从中期AMD到地图样萎缩:生物标志物、终点指标与下一代临床试验路线图
本文综述中期年龄相关性黄斑变性(iAMD)临床试验的设计难点,提出以OCT同时用于富集高危眼和作为终点指标的可配置试验设计。核心结论是OCT可测量drusen面积与体积、光感受器带完整性、高反射灶等,并可结合微视野检查捕捉功能。
要点
- iAMD可持续五年或更久才进展,而试验须约两年内得出答案。
- OCT因耐受性好、可定量且各站点可用,是富集生物标志物的最佳工具。
- 大高透射缺陷的出现与增长及外层视网膜带的进行性丢失可作为连续结构终点。
核心结论
- OCT可同时用于富集高危眼和提供终点指标,从而构建可配置的iAMD临床试验设计。
研究设计与样本
- 本文为综述,基于自然史数据建模进展与统计把握度,提出可配置试验设计。
主要发现
- iAMD可维持五年或更长时间才进展为地图样萎缩或渗出性新生血管AMD。
- 单次OCT采集可测量drusen面积与体积、光感受器带完整性、高反射灶、钙化drusen和网状假性drusen。
- 大高透射缺陷的出现与增长以及外层视网膜带的进行性丢失提供连续结构测量,可与微视野检查配对捕捉功能。
关键数值与推荐
- 富集生物标志物须能预测进展、可重复测量且可在两年内跨站点部署。
- 试验须入组最可能在该时间窗内进展的眼,并测量在进展减慢时发生变化的终点。
临床怎么用
- 在iAMD试验中优先使用OCT进行富集和终点评估,并可联合微视野检查评估功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Age-related macular degeneration (AMD) is a leading cause of irreversible legal blindness worldwide. Treatments exist for late-stage AMD, but none exists for the intermediate stage (iAMD), which precedes significant vision loss. A therapy tested in iAMD would aim to prevent or slow progression to late-stage disease, meaning geographic atrophy or exudative neovascular AMD. The difficulty is that iAMD can persist for five years or longer before it progresses, whereas a trial must reach an answer within approximately two years. Such a trial therefore has to do two things at once: enroll the eyes most likely to progress within that window, and measure an endpoint that moves when progression slows. This review identifies the enrichment and endpoint criteria that make this possible. An enrichment biomarker must predict progression, be reproducibly measured, and be deployable across sites within two years. Optical coherence tomography (OCT) is the best instrument for this purpose because it is well tolerated, quantitative, and already available wherever iAMD trials are run. A single OCT acquisition can measure drusen area and volume, photoreceptor band integrity, hyperreflective foci, calcified drusen, and reticular pseudodrusen. For the endpoint, the onset and growth of large hypertransmission defects and the progressive loss of the outer retinal bands provide continuous structural measures that can be paired with microperimetry to capture function. Drawing on natural history data to model progression and statistical power, we propose a configurable trial design in which OCT both enriches for high-risk eyes and supplies the endpoint.
引用
- Berni A, Rosenfeld PJ, Bacherini D, et al. From intermediate AMD to geographic atrophy: Biomarkers, endpoints, and a roadmap for next-generation clinical trials. Prog Retin Eye Res. 2026. PMID: 42810674. doi:10.1016/j.preteyeres.2026.101532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。